Octreotide scan

An octreotide scan is a type of scintigraphy used to find carcinoid, pancreatic neuroendocrine tumors, and to localize sarcoidosis. It is also called somatostatin receptor scintigraphy (SRS). Octreotide, a drug similar to somatostatin, is radiolabeled with indium-111,[1] and is injected into a vein and travels through the bloodstream. The radioactive octreotide attaches to tumor cells that have receptors for somatostatin (i.e. gastrinoma, glucagonoma, etc). A gamma camera detects the radioactive octreotide, and makes pictures showing where the tumor cells are in the body.

Octreotide scan
Medical diagnostics
111In-pentetreotide scintigraphy of the 41-year-old man with ectopic Cushing' syndrome caused by a neuroendocrine carcinoma of the mesentery. Radiotracer accumulation in the left thyroid in 10/2003 (arrow). The mesenterial neuroendocrine tumor became clearly visible in 4/2005 (arrow).
Synonymsocreoscan
ICD-9-CM92.18
OPS-301 code3-70c

Octreotide scanning is reported to have a sensitivity between 75% and 100% for detecting pancreatic neuroendocrine tumors.[2]

Indications

An octreotide scan may be used to locate suspected primary neuroendocrine tumours (NET) or for follow-up or staging after treatment.[3][4][5]

Procedure

The 111In-pentetreotide radiopharmaceutical is prepared from a kit in a radiopharmacy. Pentetreotide is a DTPA conjugate of octreotide.[3][6]

Approximately 200 megabecquerels of Indium-111 is injected intravenously. Imaging takes place 24 hours after injection, but may also be carried out at 4 and 48 hours.[4][7]

See also

References

  1. medicinenet.com > Carcinoid Syndrome (cont.) By Dennis Lee and Jay Marks. Retrieved Mars 2011
  2. Kwekkeboom, DJ; Krenning, EP (April 2002). "Somatostatin receptor imaging". Seminars in Nuclear Medicine. 32 (2): 84–91. doi:10.1053/snuc.2002.31022. PMID 11965603.
  3. Kwekkeboom, Dik J.; Krenning, Eric P.; Scheidhauer, Klemens; Lewington, Val; Lebtahi, Rachida; Grossman, Ashley; Vitek, Pavel; Sundin, Anders; Plöckinger, Ursula (2009). "Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Somatostatin Receptor Imaging with 111In-Pentetreotide" (PDF). Neuroendocrinology. 90 (2): 184–189. doi:10.1159/000225946. PMID 19713709.
  4. Bombardieri, Emilio; Ambrosini, Valentina; Aktolun, Cumali; Baum, Richard P.; Bishof-Delaloye, Angelica; Del Vecchio, Silvana; Maffioli, Lorenzo; Mortelmans, Luc; Oyen, Wim; Pepe, Giovanna; Chiti, Arturo (12 May 2010). "111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging" (PDF). European Journal of Nuclear Medicine and Molecular Imaging. 37 (7): 1441–1448. CiteSeerX 10.1.1.609.1835. doi:10.1007/s00259-010-1473-6. PMID 20461371.
  5. Saha, Gopal B. (2010). Fundamentals of Nuclear Pharmacy. Springer. p. 145. ISBN 9781441958600.
  6. "In 111 pentetreotide". NCI Drug Dictionary. National Cancer Institute. 2011-02-02. Retrieved 3 October 2017.
  7. Balon, H. R.; Brown, T. L. Y.; Goldsmith, S. J.; Silberstein, E. B.; Krenning, E. P.; Lang, O.; Dillehay, G.; Tarrance, J.; Johnson, M.; Stabin, M. G. (8 November 2011). "The SNM Practice Guideline for Somatostatin Receptor Scintigraphy 2.0". Journal of Nuclear Medicine Technology. 39 (4): 317–324. doi:10.2967/jnmt.111.098277. PMID 22068564.

 This article incorporates public domain material from the U.S. National Cancer Institute document "Dictionary of Cancer Terms".


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.